The abstract is read at the publisher; the summary is JClub's.
Five tumor DNA-methylation subtypes and a TMC-related five-gene CFISH signature predict overall survival in operable esophageal cancer treated with neoadjuvant ICI-based therapy, including beyond.
- Why it matters: Response prediction for immunochemotherapy in the (neo)adjuvant setting is challenging and underexplored, despite prior links between tumor monocytes and survival in advanced disease.
- What they did: In the LUD2015-005 trial, 35 operable esophageal cancer patients received a 4-week immune checkpoint inhibitor–only phase before standard-of-care combination; paired tumor and adjacent normal biopsies underwent whole-genome methylome and RNA sequencing with cell-deconvolution and integration.
- The result: Neoadjuvant ICI-based combination therapy showed improved overall outcomes, and CFISH (CXCL8, FCN1, IFI30, SLC11A1, HLA-DRA) plus methylation subtypes were highly predictive of overall survival, supporting patient stratification for immunochemotherapy.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.